抗IL-23治疗中轴型脊柱关节炎无效:对PsA相关脊柱炎事后分析的质疑
三种靶向IL-23 p40或p19亚基的单克隆抗体已获批用于银屑病,其中两种获批用于银屑病关节炎(PsA)。乌司奴单抗和瑞莎珠单抗在中轴型脊柱关节炎(axSpA)随机对照试验中无效,但PsA试验事后分析提示其可能改善 axial inflammation 所致背痛症状。本文基于axSpA无效证据提出质疑,认为该效应更可能为通用非特异性效应,现有axSpA炎症评估工具不足以充分覆盖。
要点
- 乌司奴单抗和瑞莎珠单抗在axSpA随机对照试验中未显示疗效。
- PsA试验事后分析提示抗IL-23可能改善背痛症状。
- 基于axSpA无效证据,该效应更可能为通用非特异性效应。
核心结论
- 基于axSpA随机对照试验中无效,抗IL-23治疗对axSpA相关炎症不太可能有效,PsA事后分析中背痛改善更可能为非特异性效应。
研究设计与样本
- 本文为述评/观点文章,基于三项靶向IL-23 p40或p19亚基单克隆抗体(乌司奴单抗、古塞奇尤单抗、瑞莎珠单抗)在银屑病、PsA和axSpA中的随机对照试验证据进行论证。
主要发现
- 乌司奴单抗和瑞莎珠单抗在axSpA随机对照试验中无效。
- PsA试验事后分析提示抗IL-23可能改善背痛症状,但作者认为该效应更可能为通用非特异性效应。
- 用于评估axSpA炎症的工具不足以充分覆盖此类非特异性效应。
临床怎么用
- 临床不应基于PsA事后分析将抗IL-23治疗用于axSpA相关背痛,需依据axSpA随机对照试验证据决策。
局限性
- 本文为观点文章,未提供新的随机对照试验数据,结论基于对已有试验的解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The three monoclonal antibodies ustekinumab, guselkumab and risankizumab targeting the p 40 or the 19 subunit of interleukin -23 have now been approved for the indication psoriasis and the former two also for psoriatic arthritis (PsA). Ustekinumab and risankizumab have appeared ineffective in randomised controlled trials with patients with axial spondyloarthritis (axSpA), but post-hoc analyses of PsA trials have now suggested that they may improve back pain symptoms potentially induced by axial inflammation based on PsA. Here we argue that, based on the absence of efficacy in axSpA, this is unlikely and more probably due to generic, non-specific effects, which are not adequately covered by the tools developed for the assessment of inflammation in axSpA.
引用
- Braun J, Landewé RB. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'? Ann Rheum Dis. 2021. PMID: 34656991. doi:10.1136/annrheumdis-2021-221422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。